{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-22-008134","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.351115+00:00","generated_at":"2026-06-25T22:17:50.005504+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Precigen Q1 revenue $32M (+31% YoY); Fast Track for PRGN-3006 in AML","bullets":["Total revenues $32.0M, up 31% vs $24.5M YoY; net loss $19.3M ($0.10/share).","Cash, equivalents, short- & long-term investments $142.1M as of March 31, 2022.","FDA Fast Track designation for PRGN-3006 UltraCAR-T in relapsed/refractory AML.","Phase 2 study for PRGN-2012 in RRP dosed first patient; Phase 1b expansion arm for PRGN-3006 initiated.","R&D expenses rose $2.2M (+21%) driven by clinical/preclinical program advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-22-008134","json":"https://secwatch.observer/filing/0000950103-22-008134.json","markdown":"https://secwatch.observer/filing/0000950103-22-008134.md","text":"https://secwatch.observer/filing/0000950103-22-008134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322008134/0000950103-22-008134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322008134/dp172815_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:17:50.005504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}